Neuroinhibitory ketamine and norketamine compounds, their derivatives and methods

摘要

Problem: neurological toxicity (e.g., psychomotor expression toxicity) does not lead to plasma levels and copes with gaps identified in ketamine treatment of symptoms such as pain, depression, traumatic brain injury, stroke, epilepsy, alcohol dependence or Alzheimer's disease Provide a controllable norketamine compound and a pharmaceutical containing it.For example, it is a compound having a structure which is one of the following equations.No selection